RAPT Therapeutics, Inc. RAPT
Set alert
As of Mar 6, 9:30 AM ET
- YTD
- +71.26%
- 1 year
- +547.38%
- Open
- 58.01
- Prev close
- 58.01
- Mkt cap
- 1.61B
- Vol
- 10.85M
- Avg vol
- 4.25M
- EPS
- -11.06
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 58.01
- High
- 58.01
- Beta
- 0.44
- Inst. own
- 110.57%
- Dividend
- 0.00
6M chart
Events in this range
- Nov 6, 2025Earnings: -0.65; estimate -0.88; surprise 26.14%
- Jan 20, 2026Downgrade: HC Wainwright & Co. · Buy → Neutral
- Jan 20, 2026Downgrade: TD Cowen · Buy → Hold
- Jan 20, 2026Downgrade: LifeSci Capital · Outperform → Market Perform
- Jan 20, 2026Downgrade: Wells Fargo · Overweight → Equal-Weight
- Jan 21, 2026Downgrade: Leerink Partners · Outperform → Market Perform
- Jan 21, 2026Downgrade: Barclays · Overweight → Equal-Weight
- Mar 5, 2026Earnings: -9.12; estimate -0.82293; surprise -1008.24%
Signals (17)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Feb 6, 2026 | 8 months ago |
| RSI: Overbought | Jan 20, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 16, 2026 | 9 months ago |
| SMA: Bullish | Jan 9, 2026 | 9 months ago |
| SMA: Bearish | Jan 8, 2026 | 9 months ago |
| SMA: Bullish | Jan 7, 2026 | 9 months ago |
| SMA: Bearish | Jan 5, 2026 | 10 months ago |
| MACD: Sell Signal | Dec 17, 2025 | 10 months ago |
| RSI: Overbought | Dec 10, 2025 | 10 months ago |
| MACD: Buy Signal | Nov 26, 2025 | 11 months ago |
| SMA: Bullish | Nov 24, 2025 | 11 months ago |
| SMA: Bearish | Nov 21, 2025 | 11 months ago |
| MACD: Sell Signal | Oct 22, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 21, 2025 | 1 year ago |
| RSI: Overbought | Oct 20, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 10, 2025 | 1 year ago |
| RSI: Overbought | Sep 11, 2025 | 1 year ago |
Key statistics
- Market cap
- 1.61B
- Enterprise value
- 1.57B
- Trailing P/E
- -44.46
- PEG ratio
- -0.67
- Price / sales
- 0.00
- Price / book
- 10.29
- Beta
- 0.44
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Total cash
- 0
- Total debt
- 0
- Return on equity
- -22.27%
Analyst view
- Strong buy0
- Buy0
- Hold4
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -1.03.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 5, 2026 | Dec 30, 2025 | -0.82293 | -9.12 | -8.30 | -1,008.24% |
| Nov 6, 2025 | Sep 30, 2025 | -0.88 | -0.65 | +0.23 | +26.14% |
| Aug 7, 2025 | Jun 30, 2025 | -0.61 | -0.65 | -0.04 | -6.56% |
| May 8, 2025 | Mar 31, 2025 | -2.48 | -0.64 | +1.84 | +74.19% |
| Mar 6, 2025 | Dec 31, 2024 | -3.60 | -9.12 | -5.52 | -153.33% |
| Nov 12, 2024 | Sep 30, 2024 | -0.56 | -3.76 | -3.20 | -571.43% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 21, 2026 | Barclays | down | Overweight | Equal-Weight |
| Jan 21, 2026 | Leerink Partners | down | Outperform | Market Perform |
| Jan 20, 2026 | Wells Fargo | down | Overweight | Equal-Weight |
| Jan 20, 2026 | LifeSci Capital | down | Outperform | Market Perform |
| Jan 20, 2026 | TD Cowen | down | Buy | Hold |
| Jan 20, 2026 | HC Wainwright & Co. | down | Buy | Neutral |
About RAPT Therapeutics, Inc.
RAPT Therapeutics, Inc. is a clinical-stage biopharmaceutical firm specializing in immunology. The company is dedicated to discovering, developing, and commercializing innovative oral small molecule therapies. These treatments are aimed at addressing critical unmet medical needs for patients battling oncology and inflammatory diseases. Its primary drug candidate for inflammation, RPT193, functions as a C-C motif chemokine receptor 4 (CCR4) antagonist. This compound works by selectively preventing type 2 T helper cells from migrating into inflamed tissues. In the oncology pipeline, FLX475 stands as the company's leading candidate, also an oral small molecule CCR4 antagonist. This therapy is currently undergoing Phase 1/2 clinical trials to evaluate its efficacy both as a standalone treatment and in combination with pembrolizumab for individuals with advanced cancer. RAPT Therapeutics is also engaged in the development of a hematopoietic progenitor kinase 1 (HPK1) inhibitor. Founded in 2015, the company initially operated as FLX Bio, Inc. before rebranding as RAPT Therapeutics, Inc. in May 2019. Its corporate headquarters are situated in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- Employees
- 67
- Website
- rapt.com
News
- This Biotech Was Quietly Bought Before a $58 Per Share Takeout
- This Investor Built a $56 Million Position in RAPT Last Quarter. It Was Just Acquired for $58 Per Share
- This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges
- Halper Sadeh LLC is Investigating Whether RAPT, CTGO, TBN, FOLD are Obtaining Fair Deals for their Shareholders
- Contrasting Solid Biosciences (NASDAQ:SLDB) & Rapt Therapeutics (NASDAQ:RAPT)
- Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders?
- Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders?
- Halper Sadeh LLC is Investigating Whether NWE, DHIL, RAPT are Obtaining Fair Prices for its Shareholders
- RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT
- Halper Sadeh LLC Reminds Shareholders of RAPT, PEN, CVGW, FONR of the Firm’s Investigations
Your note
Sign in to keep a note on RAPT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRAUNSTEIN SCOTT N. | Director | Stock Award(Grant) | Jan 29, 2026 | 4,956 |
| DOMBKOWSKI ASHLEY L | Director | Stock Award(Grant) | Jan 29, 2026 | 4,956 |
| GIORDANO MICHAEL F | Director | Stock Award(Grant) | Jan 29, 2026 | 4,956 |
| GRAY MARY ANN | Director | Stock Award(Grant) | Jan 29, 2026 | 4,956 |
| KOZICK LINDA | Director | Stock Award(Grant) | Jan 29, 2026 | 4,956 |
| LYONS-WILLIAMS LORI | Director | Stock Award(Grant) | Jan 29, 2026 | 4,956 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 10.08% | 2,794,000 | 162.11M | Dec 30, 2025 |
| TCG Crossover Management, LLC | 9.32% | 2,582,408 | 149.83M | Dec 30, 2025 |
| FCPM III Services B.V. | 6.62% | 1,833,333 | 106.37M | Dec 30, 2025 |
| Orbimed Advisors LLC. | 5.93% | 1,642,891 | 95.32M | Dec 30, 2025 |
| RTW Investments LP | 5.91% | 1,637,165 | 94.99M | Dec 30, 2025 |
| Foresite Capital Management VI LLC | 5.64% | 1,562,500 | 90.66M | Dec 30, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.98% | 827,036 | 47.98M | Dec 30, 2025 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.98% | 547,644 | 31.77M | Dec 30, 2025 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 0.99% | 273,226 | 15.85M | Dec 30, 2025 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.75% | 207,602 | 12.05M | Dec 30, 2025 |
| iShares Trust-iShares Biotechnology ETF | 0.48% | 131,880 | 7.65M | Dec 30, 2025 |
| -Fidelity SAI Merger Arbitrage Fund | 0.45% | 125,000 | 7.25M | Jan 30, 2026 |